Previous Article | Next Article ![]()
Journal of Virology, May 2007, p. 4981-4990, Vol. 81, No. 10
0022-538X/07/$08.00+0 doi:10.1128/JVI.02361-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

,
Konstantin Alekseev,1,
Anastasia Vlasova,1,
Xinsheng Zhang,1
David Spiro,2
Rebecca Halpin,2
Shiliang Wang,2
Elodie Ghedin,2 and
Linda J. Saif1*
Food Animal Health Research Program, Department of Veterinary Preventive Medicine, Ohio Agricultural Research and Development Center, The Ohio State University, 1680 Madison Avenue, Wooster, Ohio 44691-4096,1 The Institute for Genomic Research, Rockville, Maryland2
Received 27 October 2006/ Accepted 1 March 2007
|
|
|---|
|
|
|---|
Bovine CoV (BCoV) is a member of group 2, along with human CoVs (HCoV-OC43 [3, 45] and HCoV-HKU1 [48, 49]), mouse hepatitis virus (MHV) (14), rat CoV (1), porcine hemagglutinating encephalomyelitis virus (30), equine CoV (13), and canine respiratory CoV (11, 12, 31). BCoV is an important agent of neonatal calf diarrhea and is also associated with an acute diarrhea of adult cattle referred to as winter dysentery (34, 35). Besides infecting the small and large intestines of calves, BCoV also possesses a tissue tropism for the upper and lower respiratory tracts (15, 23) and has recently been associated with the bovine respiratory disease complex in feedlot cattle (6, 15, 17, 23, 41). Based on experimental and field studies, it was suggested that both the fecal-oral and nasal modes of transmission for BCoV might be important in the field (6, 8, 15, 23, 31, 32, 34, 41).
CoVs, like other RNA viruses, represent a quasispecies, increasing the possibility of adaptive mutations and interspecies transmission (9). Prior and recent findings support the likelihood that the group 2b CoV severe acute respiratory syndrome (SARS) is a zoonotic infection of animal origin (21, 24, 25, 29, 31, 32, 46, 50). Recently, CoVs have been recognized as important pathogens in captive or wild ruminants in the United States, including sambar deer (Cervus unicolor), white-tailed deer (WTD; Odocoileus virginianus), waterbuck (Kobus ellipsiprymnus), and elk (Cervus elephus) (26, 42). Additionally, some wild ruminants such as caribou (Rangifer tarandus) and musk oxen (Ovibus moschatus) were found to be BCoV seropositive (10), and CoVs were detected in fecal samples from sitatunga (Tragelaphus spekei) and waterbuck (K. ellipsiprymnus) by electron microscopy (EM) and a BCoV-specific enzyme-linked immunosorbent assay (ELISA) (4). In these studies, the captive and wild ruminant CoV isolates showed close antigenic relationships to BCoV strains in vitro (4, 10, 42) or in vivo (42). However, some of the CoV strains (from sitatunga and waterbuck in England) detected by EM failed to replicate or induce clinical signs after experimental oral inoculation of gnotobiotic (Gn) calves, and these strains could not be adapted to growth in BCoV-susceptible cell cultures (4).
In this paper, we describe the isolation of a bovine-like CoV from a giraffe fecal sample and comparative analyses of its antigenic and genomic properties with respect to those of BCoV strains.
|
|
|---|
Of interest, other ruminant species (banteng, sable antelope) at the park that were housed in a separate barn about 0.5 mi from the giraffe barn developed a similar outbreak of diarrhea within 1 to 2 weeks preceding the giraffe outbreak. Feces collected from the sable antelope and tested by immune EM (IEM) with hyperimmune antiserum to BCoV confirmed the presence of a CoV reactive with antiserum to BCoV in this animal (L. J. Saif, unpublished data, 2003).
There were cattle farms about 2 to 5 miles from the wild-animal park, but there were no shared services or direct traffic between the cattle farms and the park and no information about diarrhea outbreaks in the cattle farms. However, within the park, the same individuals were responsible for feeding the various animals and the same dump truck that was used to haul the manure was also used to haul fresh bedding. Also, starlings were present in the giraffe and other ruminant barns.
Reference viruses and antisera. The BCoV strains and corresponding hyperimmune antisera prepared in guinea pigs included calf diarrhea strains (Mebus and DB2), winter dysentery strains (DBA and TS), and respiratory strains (67NS, 220NS, and 440NS), as described previously (17, 43). The DB2 strain was isolated from a calf with diarrhea, and its virulence was maintained by serial passage of infected feces in Gn calves. The transmissible gastroenteritis virus (TGEV) Purdue-P115 and porcine respiratory CoV (PRCV) ISU-1 strains were described previously (37). All viruses were titrated in fluorescent focus neutralization (FFN) assays. Reference TGEV Purdue-P115 and PRCV ISU-1 antisera were also produced in seronegative guinea pigs or Gn pigs as described previously (37, 47).
Gn calves. Preparation of fecal sample inocula, inoculation methods, and sample collection were described previously (5). A diagram of the experimental design illustrating the initial giraffe CoV inoculum and subsequent serial passage in Gn calves is shown in Fig. 1. Briefly, 3 ml of a giraffe fecal sample (GiCoV-OH3-FS/WD1421) was diluted 1:10 with minimum essential medium (MEM; Invitrogen Corp., Carlsbad, CA), supplemented with 1% antibiotic-antimycotic solution (Invitrogen Corp., Carlsbad, CA) and 1% NaHCO3 (pH 7.2), and filtered sequentially through 0.8-µm, 0.45-µm, and 0.22-µm syringe filters (Nalge Nunc International, Rochester, NY). The fecal filtrate was used to orally inoculate an 8-day-old Gn calf (B566). All calves were fed with human infant formula (Similac; Ross Laboratories, Columbus, OH), and fecal samples were collected daily as described previously (5). Calf B566 was euthanized at postinoculation day 4 (PID4), and small and large intestinal contents (SIC and LIC, respectively) were collected. A second 13-day-old Gn calf (B567) was orally inoculated with the GiCoV-OH3-containing SIC-plus-LIC sample from the first calf. The calf-passaged sample was diluted 1:5 in MEM supplemented with antibiotic-antimycotic solution. After necropsy (at PID3), LIC collected from this calf was used as GiCoV source material for RNA extraction and sequencing (GiCoV-OH3-Gn calf). Two additional calves, B572 and B573 (8 to 9 days of age), were inoculated as described for B567, with the GiCoV-OH3 LIC sample from Gn calf B567, and fecal samples from these calves were collected daily. From diarrhea onset (PID3) through PID5 (end of severe diarrhea), these two calves were orally given Bounce Back Electrolyte-Energy Supplemented for dehydrated calves (The Manna Pro Corporation, Chesterfield, MO) to alleviate the virus-induced dehydration. At PID21, calf B572 was challenged with virulent BCoV-DB2 (maintained by serial passage in Gn calves) and calf B573 was rechallenged with the GiCoV-OH3-containing LIC sample from Gn calf B567. Blood was collected at PID0, PID14, and PID21 and at postchallenge day 7.
![]() View larger version (12K): [in a new window] |
FIG. 1. Diagram of the experimental design, illustrating the initial giraffe CoV inoculum and its subsequent serial passage in Gn calves. Parts: 1, inoculation of the original GiCoV-OH3-containing feces into a Gn calf (B566); 2, second passage of GiCoV-OH3 in a Gn calf (B567); 3, demonstration of cross-protection between GiCoV-OH3 and BCoV-DB2 in which two Gn calves (B572 and 573) were initially inoculated with GiCoV-OH3 and then either rechallenged with GiCoV (B572) or challenged with BCoV-DB2 (B573).
|
ELISA. An indirect antigen capture ELISA and an antibody capture ELISA with a pool of three monoclonal antibodies (MAbs) directed against the S, N, and HE structural proteins of BCoV strain DB2 were used to detect GiCoV in fecal suspensions and GiCoV-specific antibody in serum samples as previously described (16, 17, 38, 39).
Western blotting. Polyacrylamide gel electrophoresis and Western blot assays of GiCoV- or mock-infected human rectal tumor 18 (HRT-18) cell supernatants containing viral proteins were performed according to standard protocols as described by Sambrook et al. (36). Clarified virus- or mock-infected HRT-18 cell supernatants were lysed in 1x loading buffer (Fermentas, Hanover, MD) in the presence of 200 mM dithiothreitol. After proteins were separated on gels and transferred to nitrocellulose membranes, they were stained with a pool of BCoV-Mebus spike and nucleoprotein MAbs and a horseradish peroxidase-conjugated anti-mouse immunoglobulin G serum was used as the secondary antibody.
RT-PCR. The total RNA was extracted from giraffe fecal samples with TRIZOL LS reagent (Gibco, Life Tech, Grand Island, NY) according to the manufacturer's instructions. A one-step reverse transcription (RT)-PCR assay was performed as previously described (5). The oligonucleotide primers used in the RT-PCR were designed from the published sequence of the polymerase and nucleoprotein genes of the CoV strains. The following primer pairs were designed or modified and used for genome detection of BCoV and the related ruminant CoVs. Pan-CoV-specific forward (IN-2deg; GGGDTGGGAYTAYCCHAARTGYGA) and reverse (IN-4deg; TARCAVACAACISYRTCRTCA) universal primers targeting a 452-bp fragment of the polymerase gene were modified in our laboratory from those of Ksiazek et al. (20). Group 2-specific forward (Gr2F; GAAGGCTCDGGAARGTCTG) and reverse (Gr2R; CCTCTYTTHCCAAAACACTG) primers capable of detection of all group 2 CoVs targeting a 300-bp fragment of the nucleocapsid gene were developed and used. BCoV-specific forward (NOF; GCAATCCAGTAGTAGAGCGT) and reverse (NOR; CTTAGTGGCATCCTTGCCAA) primers targeting a 729-bp fragment of the nucleocapsid gene and highly specific for BCoV and bovine-like CoVs were developed and used.
Virus isolation. Monolayers of HRT-18 cell cultures from cells cloned in our laboratory were used for virus isolation as described previously (2, 17). Cells were inoculated, in duplicate wells, with ELISA- and RT-PCR-positive fecal supernatants, adsorbed at 37°C for 1 h, and then advanced minimum essential medium (AMEM) containing 5 µg/ml pancreatin (Sigma Chemical Co., St. Louis, MO) was added. Cultures were incubated at 37°C in a 5% CO2 atmosphere and examined daily for evidence of cytopathic effects (CPE) or assayed for the presence of CoV by RT-PCR (as described above).
Plaque induction. The detailed procedures for BCoV plaque induction have been described previously (2, 17). After addition of serial virus dilutions (101 to 1010) in AMEM to HRT-18 cell monolayers in six-well plates (Costar, Cambridge, MA), monolayers were incubated at 37°C for 1 h to allow virus adsorption. The plates were then overlaid with AMEM containing 1.6% Noble agar (BBL, Cockeysville, MD) plus 0.1% neutral red (Sigma Chemical Co., St. Louis, MO), 0.1% pancreatin, and 1% DEAE dextran (Sigma Chemical Co., St. Louis, MO) (AMEM plus). Plates were inverted and incubated at 37°C in a 5% CO2 atmosphere for 3 to 5 days, and induction of plaques was assessed.
Virus purification. The cloned GiCoV-OH3 isolate was purified from the HRT-18 cell culture supernatants as described previously (17). Briefly, the clarified, virus-infected cell culture supernatants were purified by ultracentrifugation (112,000 x g for 2 h) on 20% to 50% sucrose density gradients in an ultracentrifuge (L8-M; Beckman, Schaumburg, IL).
Hemagglutination (HA) and receptor-destroying enzyme (RDE) activity tests. HA tests were conducted by the microtiter method with V-bottom plates (Dynex Tech Inc., Chantilly, VA) as described previously (16, 17). Briefly, serial twofold dilutions of the purified CoV strains were prepared in 25 µl of Veronal-buffered saline solution (pH 7.2) and mixed with 25-µl suspensions of mouse (0.8%) or chicken (0.4%) erythrocytes. Mixtures were incubated (4°C or 37°C for 1 h). After incubation, titers were expressed as the reciprocal of the highest dilution of virus that caused complete HA. Plates were incubated at 37°C for an additional 4 h to assess RDE activity, which was expressed as the reciprocal of the highest dilution of virus resulting in complete disappearance of the HA patterns (17).
HA inhibition (HI) assay. The procedure for the HI test has been described elsewhere (17). Briefly, all serum samples were treated with kaolin and packed mouse erythrocytes to remove nonspecific hemagglutinins. Then, 25 µl of antiserum (in serial twofold dilutions) was mixed with 25 µl of 8 HA units of purified CoV strains and incubated at 22°C for 1 h. After incubation, 50 µl of a 0.8% suspension of mouse erythrocytes was added and the mixture was incubated at 22°C for 2 h. Results were considered positive when HA (pellet formation) was inhibited.
FFN assay. The FFN test was performed with 50% fluorescent focus units (50% FFU/0.1 ml) of GiCoV or the BCoV strains, which was calculated by performing cell culture immunofluorescence (CCIF) tests with 96-well microtiter plates (Costar, Cambridge, MA) as described previously (17). Briefly, to define the virus titer in the CCIF assay, 7-day-old monolayers of HRT-18 cell cultures in 96-well plates were inoculated with 10-fold serial dilutions of virus in AMEM containing 0.025 µg/ml pancreatin. After incubation for 18 h at 37°C in a 5% CO2 atmosphere, cells were fixed with 80% acetone and stained with fluorescein isothiocyanate-conjugated hyperimmune Gn calf antiserum to BCoV (Mebus strain). The cells were considered positive for CoV antigen when they showed specific cytoplasmic fluorescence distinct from any background reactions in controls. The percentage of positive cells in each specimen was determined after the examination of five different fields of view with a fluorescence microscope (Olympus, Tokyo, Japan), and the number of FFU per milliliter was calculated. In the FFN test, fourfold serially diluted guinea pig anti-BCoV and anti-TGEV (group 1 CoV control) sera and bovine anti-GiCoV-OH3 serum samples were mixed with 50% FFU/0.1 ml of the virus isolate or BCoV strain, incubated for 60 min at 37°C, and added to 7-day-old monolayers of HRT-18 cells in 96-well plates. The next steps were the same as for the CCIF assay described above. The FFN test for TGEV Purdue-P115 and PRCV ISU-1 was performed similarly to that for BCoV, except that 3-day-old swine testicular cells were used and virus was detected with mouse MAbs against TGEV, followed by fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin G (KPL, Gaithersburg, MD) (47).
Sequencing. (i) RNA extraction. RNA was extracted as described earlier from the original giraffe fecal sample (GiCoV-OH3-FS), the supernatant of HRT-18 cell cultures from the fourth serial passage (two passages on HRT-18 cells, followed by plaque purification and one more passage of plaque-purified virus) of the GiCoV-OH3 strain (GiCoV-OH3-CC) and an LIC sample from the second passage of GiCoV-OH3 in a Gn calf (GiCoV-OH3-Gn calf).
(ii) cDNA synthesis. Specific oligonucleotide primers were designed with BCoV (NC_003045) as a reference genome and purchased from Invitrogen (Carlsbad, CA). Primers were designed every 500 bp along the genome. An M13 sequence tag was added to the 5' end of each primer to be used for sequencing (F primers, TGTAAAACGACGGCCAGT; R primers, CAGGAAACAGCTATGACC). Primer sequences are available from the authors. RT-PCRs were performed with 50 to 200 ng of CoV RNA with QIAGEN OneStep RT-PCR kits (QIAGEN, Valencia, CA) according to the manufacturer's instructions. Duplicate reaction mixtures were analyzed by agarose gel electrophoresis for quality control. Amplicons were prepared for sequencing by incubation at 37°C for 60 min with 0.5 U of shrimp alkaline phosphatase (USB, Cleveland, OH) and 1 U of exonuclease I (USB) to inactivate the remaining deoxynucleoside triphosphates and to digest the single-stranded primers. The enzymes were inactivated by incubation at 72°C for 15 min.
(iii) Sequencing and sequence editing. Sequencing reactions were performed with a standard high-throughput sequencing system by using Big Dye Terminator chemistry (Applied Biosystems) with 2 µl of template cDNA. Each amplicon was sequenced from each end with M13 primers (F primer, TGTAAAACGACGGCCAGT; R primer, CAGGAAACAGCTATGACC). Sequencing reactions were analyzed on an ABI 3730 sequencer.
Sequencing reads were downloaded, trimmed to remove amplicon primer-linker and low-quality sequences, and assembled with TIGR Assembler (from The Institute for Genomic Research [TIGR], www.tigr.org/software/assembler/). To close gaps between assembled contigs, strain-specific primers were designed, RT-PCRs were performed, and amplicons were sequenced as described above. Additional primer design, cDNA synthesis, and sequencing were performed to ensure greater-than-fourfold sequence coverage along the CoV genomes.
Assemblies were manually edited with CloE (Closure Editor), a TIGR program for editing assemblies. All apparent polymorphisms were checked against reference data, and ambiguities were analyzed by RT-PCR and cloning. Each assembly was analyzed with Viral Genome ORF Reader (VIGOR), a program designed at TIGR to predict viral protein sequences. VIGOR checked segment length, alignments with reference sequences, and fidelity of reading frames; correlated amino acid mutations with nucleotide polymorphisms; and detected potential sequence errors.
Sequence analyses. The reference CoV genome sequences from GenBank compared for phylogenetic analyses are as follows. The group 1 CoVs were HCoV-229E (NC_002645), HCoV-NL63 (NC_005831), PEDV (NC_003436), FIPV (NC_007025), and TGEV (NC_002306). The group 2a CoVs were HCoV-0C43 (NC_005147), HCoV-HKU1 (NC_006577), MHV-A59 (NC_001846), BCoV-Mebus (U00735), BCoV-ENT (NC_003045), and BCoV-DB2 (DQ811784). The sole group 2b CoV was SARS-Tor2 (NC_004718). The sole group 3 CoV was infectious bronchitis virus strain Beaudette (NC_001451). Sequence alignment and phylogenetic analysis were performed by the ClustalW method of the Lasergene Biocomputing Software (DNASTAR Inc., Madison, WI). The GiCoV-OH3 sequence was compared with the human and animal CoV strains in GenBank. The deduced amino acid sequences were then assembled and analyzed with the MegAlign module of the Lasergene Biocomputing Software.
Nucleotide sequence accession numbers. The sequences determined in this study were submitted to GenBank and assigned accession numbers EF424623, EF424622, and EF424624.
|
|
|---|
![]() View larger version (86K): [in a new window] |
FIG. 2. IEM of (a) the giraffe CoV (GiCoV-OH3) in feces from the second passage in a Gn calf (B567) and (b) plaque-isolated, sucrose-purified GiCoV-OH3 from an HRT-18 cell culture. Both samples were incubated with Gn-calf hyperimmune antiserum to BCoV, leading to the specific viral-antibody aggregates with an antibody fringe evident on particles in panel a. S denotes longer spikes, and HE indicates a shorter hemagglutinin layer. The bar represents 100 nm.
|
|
View this table: [in a new window] |
TABLE 1. HA and RDE titers of giraffe CoV (GiCoV-OH3) and BCoV strains
|
|
View this table: [in a new window] |
TABLE 2. Two-way HI and FFN test results for GiCoV-OH3, BCoV, TGEV, and PRCV strains
|
![]() View larger version (28K): [in a new window] |
FIG. 3. Demonstration of cross-reactivity between BCoV-DB2 and GiCoV-OH3 by Western blotting with a pool of BCoV-Mebus spike and nucleoprotein MAbs. Lanes: 1, supernatant of HRT-18 cells infected with BCoV-DB2; 2, supernatant of HRT-18 cells infected with GiCoV-OH3; 3, protein ladder (Precision Plus protein standards, dual color; Bio-Rad, Hercules, CA); 4, supernatant of mock-infected HRT-18 cells. *, the smaller size of the band corresponding to the spike protein is due to proteolytic cleavage between the S1 and S2 subunits. The glycosylated S1 subunit represented on the blot has a molecular mass of about 120 kDa.
|
Genetic characterization of the GiCoV-OH3 isolate. Genomic characterization was performed by full-length genome sequencing of the original GiCoV (GiCoV-OH3-FS), cell-adapted GiCoV (GiCoV-OH3-CC), and Gn-calf-passaged GiCoV (GiCoV-OH3-Gn). The GiCoV RNA genome was organized into 10 open reading frames and contains a total of 31,002 nucleotides. A comparison of GiCoV open reading frames with those of BCoVs revealed the same pattern of genome organization, with minor differences in the lengths of the spike and 4.8-kDa proteins (Fig. 4). The numbers of predicted structural and nonstructural proteins (NSPs) of the isolate are shown in Fig. 4.
|
View larger version (4K): [in a new window] |
FIG. 4. Schematic diagram representing the genome organization of the GiCoV-OH3 isolate and BCoV. RdRp, RdRp replication protein complex; 32, 32-kDa NSP; HE, hemagglutinin-esterase protein; S, spike glycoprotein; 4.9, 4.9-kDa NSP; 4.8, 4.8-kDa NSP; 12.7, 12.7-kDa NSP; E, small membrane/envelope protein; M, membrane protein; N, nucleoprotein. Below the diagram, the length of each protein in amino acids is represented for the GiCoV-OH3 isolate and the BCoV-Mebus and BCoV-ENT strains. Protein lengths that differ between GiCoV-OH3 and BCoVs are underlined.
|
|
View this table: [in a new window] |
TABLE 3. Amino acid sequence differences observed in ORF 1ab and HE, E, M, N, and nonstructural proteins of the GiCoV-OH3 isolate and those of BCoV-Mebus, BCoV-ENT, and BCoV-DB2
|
|
View this table: [in a new window] |
TABLE 4. Amino acid sequence differences between the spike glycoprotein of the GiCoV-OH3 isolate and those of BCoV-Mebus, BCoV-ENT, and BCoV-DB2
|
Phylogenetic analysis with the full-length nucleotide sequences of the CoV strain (GiCoV-OH3) newly isolated from giraffe feces and reference CoV strains from different groups demonstrated that GiCoV belongs to CoV group 2, forming a tight cluster with BCoV strains (Fig. 5).
![]() View larger version (6K): [in a new window] |
FIG. 5. Phylogenetic analysis of the GiCoV-OH3 isolate based on full-length genome sequencing. For phylogenetic tree construction, the following CoVs were used: group 1, HCoV-229E, HCoV-NL63, PEDV, FIPV, and TGEV; group 2a, BCoV-ENT, BCoV-DB2, BCoV-Mebus, HCoV-OC43, HCoV-HKU1, and MHV-A59; group 2b, SARS-CoV; group 3, infectious bronchitis virus (IBV).
|
T) of GiCoV-OH3-CC, compared to the original GiCoV-OH3-FS and the GiCoV-OH3-Gn calf fecal sample obtained after the second passage in a Gn calf. |
|
|---|
Sambar deer (C. unicolor), WTD (O. virginianus), waterbuck (K. ellipsiprymnus), and elk or wapiti (C. elephus) were shown to harbor CoVs antigenically (cross-neutralizing) indistinguishable from BCoV, and these CoVs experimentally infect calves (26, 31, 32, 42). Unfortunately, complete genome sequencing of these CoVs has not been done to assess their genetic similarity to BCoV. To our knowledge, there is no report of the isolation and characterization of CoVs from giraffes. Here we report the first isolation and detailed characterization, including the complete genome sequence analysis, of a bovine-like CoV from feces of a giraffe with clinical signs of diarrhea. Although the source of the GiCoV-OH3 strain that caused the diarrheal outbreak among giraffes (in a wild-animal park in Ohio) is unknown, the virus may have originated from other wild ruminants in the park or outside the park (WTD) or even nearby (2 miles distant) cattle farms.
After the second passage in HRT-18 cell cultures, a typical CoV CPE was observed for GiCoV-OH3. Interestingly, the typical CPE appeared after only 36 to 48 h of inoculation, whereas it usually takes longer for BCoV strains (3 to 5 days). Also, the titer of the isolated virus was very high, 4.7 x 109 FFU/ml by CCIF assay, whereas other BCoV strains usually grow to titers of 106 to 109 FFU/ml (17, 43, 44). CoVs, like other RNA viruses, represent a quasispecies (9), which increases the potential for adaptive mutations and interspecies transmission. The isolate GiCoV-OH3 was from a 24-year-old male giraffe with diarrhea, and when inoculated into four BCoV-seronegative Gn calves, both the original isolate and the Gn-calf-passaged virus caused severe diarrhea with virus shedding within 2 to 3 days, although the infectious titer of the original giraffe feces was low. In comparison, diarrhea and virus shedding usually begin at PID3 to PID7 in Gn calves inoculated with BCoV (5). No virus shedding or diarrhea occurred after a challenge with virulent BCoV-DB2 in the calf initially inoculated with GiCoV-OH3. This complete cross-protection confirms the close antigenic relatedness in vivo between BCoV-DB2 and the giraffe CoV-OH3 isolate. Furthermore, in vitro cross-reactivity between the GiCoV-OH3 and BCoV-DB2 spike and nucleocapsid proteins was demonstrated by Western blotting with pooled BCoV-Mebus spike and nucleoprotein MAbs.
Sequence analysis demonstrated a deletion in the presumed hypervariable region (7, 28, 51) of the GiCoV-OH3 spike gene compared to that of the BCoV-Mebus, BCoV-ENT, and BCoV-DB2 strains. Yoo and Deregt (51) reported that a single point mutation in this region of the BCoV-Quebec strain could allow the virus to escape from immunological selective pressure, as tested in radioimmunoprecipitation assays. Giraffe isolate GiCoV-OH3 showed an increased level of replication in cell culture (compared to BCoV strains) and high virulence upon initial passage in a Gn calf and one of the original giraffe hosts. We speculate that the five-amino-acid deletion in the hypervariable region of the spike protein might influence viral replication in the Gn calf in vivo or in HRT-18 cells in vitro. In contrast, a large deletion in the N-terminal region of the spike protein was shown to be critical in the case of the naturally occurring S gene deletion mutant of the highly virulent porcine enteric TGEV, resulting in the attenuated PRCV strain that emerged independently in Europe and the United States in the 1980s (31, 32).
Comparisons of the entire genome sequences revealed the closest relatedness between GiCoV-OH3 and BCoV-ENT and slightly more distant relatedness between GiCoV-OH3 and BCoV-DB2, whereas GiCoV-OH3 and BCoV-Mebus were the most distantly related. The high homologies of nucleotide and amino acid sequences and the phylogenetic analysis suggest that GiCoV and BCoV strains may have evolved concurrently from a common ancestor. More amino acids were common to GiCoV-OH3 and BCoV-ENT and to GiCoV-OH3 and BCoV-DB2 than to the Mebus strain, suggesting that bovine CoVs have evolved since the time of isolation of BCoV-Mebus in 1972 or that the high passage level of the Mebus strain in multiple cell lines (27) may have selected for such genomic differences. Alignment of the amino acid sequences of the spike proteins confirmed previous findings (7) concerning a higher level of variability in the S1 subunit (33 polymorphic positions in S1) compared to the S2 subunit (12 in S2) (Table 4) and revealed that most of the detected substitutions were conserved among the enteropathogenic BCoV strains. Interestingly, the six mutations unique to GiCoV-OH3, including the five-amino-acid deletion, were clustered within the region that is identified as hypervariable for other CoVs (7, 28, 51), suggesting that this region in the GiCoV-OH3 spike protein is also prone to selective immunologic pressure. Previously, it was reported that one of the polymorphic positions in the spike protein, at amino acid 531, discriminated between enteric (aspartic acid [D] or asparagines [N]) and respiratory (glycine [G]) BCoV strains (7, 51). We confirmed the presence of an aspartic acid (D) in this position in enterotropic GiCoV-OH3. In our earlier investigations, we compared the antigenic and biological properties of respiratory and enteric BCoV strains (17, 43) and found that respiratory and enteric BCoVs differed genetically on the basis of the molecular analysis of the S1 subunit of the spike protein (18). Further genetic and antigenic studies are required to determine the biological role and importance of the identified genetic differences in the GiCoV-OH3 genome compared to BCoVs.
Antigenic variation by virus neutralization and HI tests and biological variation in HA and RDE activities were observed among enteric and respiratory BCoV strains but were independent of their clinical origin (enteric or respiratory) (17, 43). In this study, the GiCoV isolate also possessed biological (in HA and RDE activity tests) and antigenic (in HI and FFN tests) properties similar to those of both enteric and respiratory BCoV strains. These findings and the absence of reactivity in HI and FFN tests with TGEV or PRCV antiserum demonstrated that the newly isolated bovine-like GiCoV-OH3 strain belongs to group 2a and is distant from group 1 CoVs. This result was also confirmed by a phylogenetic analysis comparing the full-length genomic nucleotide sequences from all three groups of CoVs.
Our results have confirmed again that wild ruminants are an important natural reservoir for bovine-like CoVs and some of these CoVs can be transmitted experimentally to domestic cattle. Although the risk of transmission from giraffes to cattle may seem remote in the United States, this is likely not the case in Africa, where the grazing areas for giraffes and cattle overlap, allowing introduction of new strains of CoVs from wild ruminants into cattle and their possible establishment in the cattle population or vice versa, with cattle strains being transmitted to and becoming established in wild ruminants. Moreover, the area of Ohio where the captive giraffe was located (a wildlife park) also is in an area with cattle farms nearby. We previously showed that CoVs can be transmitted by aerosols and the fecal-oral route and that bovine CoVs can infect turkey poults (19). Thus, the risk of airborne, mechanical (feed, veterinary trucks, etc.), and wild-bird transmission of a GiCoV to cattle in the vicinity or vice versa is not improbable. Also, a bovine-like CoV was isolated from a captured WTD in Ohio and antibodies to BCoV were confirmed in the serum of the WTD (42). Because WTD are also present in high numbers throughout Ohio and in the vicinity of the wild-animal park, they could also be a source of CoV infection for the captive wild ruminants in the wild-animal park.
In summary, we demonstrated that wild-ruminant CoVs are biologically, antigenically, and genetically similar to bovine CoVs from domestic cattle, suggesting the possibility of interspecies transmission and adaptation of CoVs to new hosts among the ruminant species.
This work was supported by grant R21 AI062763 from the NIAID, NIH. Salaries and research support were provided by state and federal funds provided to the Ohio Agricultural Research and Development Center, The Ohio State University.
Published ahead of print on 7 March 2007. ![]()
Present address: Department of Virology, Faculty of Veterinary Medicine, Istanbul University, Avcilar 34320, Istanbul, Turkey. ![]()
M.H., K.A., and A.V. contributed equally to this paper. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»